chrisvoncsefalvay/vaers-outcomes huggingface dataset:
improperly stored vaccine administered after temperature excursion; Information has been received from a licensed practical nurse referring to a patient of unknown age and gender. The patient's concomitant medication, pertinent medical history, drug reactions or allergies were not provided.      On 10-SEP-2021, temperature excursion occurred for rotavirus vaccine, live, oral, pentavalent (ROTATEQ) (lot # 1707460 has been verified to be valid, expiration date 14-MAR-2022) and haemophilus b conjugate vaccine (meningococcal protein conjugate) (LIQUID PEDVAXHIB) (lot # T026961 has been verified to be valid, expiration date 02-APR-2023). On 13-SEP-2021, the patient was vaccinated with both rotavirus vaccine, live, oral, pentavalent (ROTATEQ) (oral; dose details were not provided) and haemophilus b conjugate vaccine (meningococcal protein conjugate) (LIQUID PEDVAXHIB) (route and dose details were not provided) for prophylaxis (incorrect product storage).   The storage temperature of both vaccines was 48.7 degrees Fahrenheit for a time frame of 10 minutes. There was no previous temperature excursion. No product quality complaint was reported.
Headache, Myalgia, NauseaVomiting, :chills; did not take temp" Narrative:
On dose #2 of prevnar 13 she also has RotaTeq vaccine and she developed a full body rash with her face being the worst. She also developed a fever.   This dose of prevnar 13 (3rd dose) she received this vaccine only. She has had a fever as high as 101.8, developed a runny nose and cough. The fever was at 99.0 6am the following morning of her vaccine. The runny nose/sneezing/cough/hoarseness continued to develop throughout the day. She was in good health leading up to the vaccine
fever; headache; body aches; neckpain; bedridden; swelling; off label use; he received a Menveo liquid portion only of the vaccination; Inappropriate dose of vaccine administered; Inappropriate age at vaccine administration; redness; This case was reported by a physician via call center representative and described the occurrence of fever in a 84-year-old male patient who received Men ACWY-CRM NVS (Menveo) for prophylaxis.   On 2nd May 2019, the patient received the 1st dose of Menveo (intramuscular). On 2nd May 2019, less than a day after receiving Menveo, the patient experienced erythema, off label use, inappropriate preparation of medication, inappropriate dose of vaccine administered and inappropriate age at vaccine administration. On 3rd May 2019, the patient experienced fever, headache, general body pain, neck pain, bedridden and swelling. On an unknown date, the outcome of the fever, headache, general body pain, neck pain, bedridden, erythema and swelling were recovered/resolved and the outcome of the off label use, inappropriate preparation of medication, inappropriate dose of vaccine administered and inappropriate age at vaccine administration were unknown.   The reporter considered the fever, headache, general body pain, neck pain, bedridden, erythema and swelling to be unrelated to Menveo.  Additional information received were as follows: The physician reported that he received a Menveo liquid portion only of the vaccination. The physician called to report the side effects to the physician office and was told he only received the saline portion of the vaccine so the reactions were not vaccine related, which led to off label use, inappropriate preparation of medication, inappropriate dose of vaccine administered and inappropriate age at vaccine administration  The physician noted that he went else where to have titres drawn and only the A portion was low and had not received another dose yet. 1 day after receiving Menveo, the patient experienced fever, headache, general body pain, neck pain, bedridden and swelling The physician reported the headache and body aches were extremely bad and continual fever. The physician noted that he was bedridden for about 48 hours. All issues resolved, but he was concerned about worse events if he repeated the vaccine to get the full dose. The healthcare professional was transferred to MIS for discussion.
When she blew her nose, it's bloody; Myalgia; Fatigue; This spontaneous case was reported by a consumer and describes the occurrence of EPISTAXIS (When she blew her nose, it's bloody), MYALGIA (Myalgia) and FATIGUE (Fatigue) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No medical history was provided by the reporter.  Concomitant products included PREDNISONE and MELOXICAM for an unknown indication.    On 02-Aug-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced EPISTAXIS (When she blew her nose, it's bloody), MYALGIA (Myalgia) and FATIGUE (Fatigue). At the time of the report, EPISTAXIS (When she blew her nose, it's bloody), MYALGIA (Myalgia) and FATIGUE (Fatigue) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No treatment information was provided by the reporter.
Dry mouth/tongue. Attempted to drink extra water, it didn't help. My mouth was quite dry. It was mildly uncomfortable. It continued after eating. I went to sleep around 1:30 AM, it was gone when I woke up this morning, April 8 2021 (around 10am)
Report A0373114A describes the occurrence of dermatitis in a 27 year old female who received hep A vaccine. This report was received from a medical assistant. Medical history was not specified. The vaccinee has a history of allergy to sulfa. Concurrent medications include Zovia, multivitamins and Differin gel. On 6/25/02, the vaccinee received the first injections of Havrix. On 6/27/02, the vaccinee experienced dermatitis on her legs and arms described as "discrete papules with surrounding clear zones" and mild itching. The reporter stated that the events were probably related to Havrix. As of 6/28/02, the adverse events were unresolved.
This spontaneous report as received from a licensed vocational nurse refers to an unspecified amount of patients of unknown age and gender. There was no information on the patients' concurrent conditions, medical history and concomitant medications. On an unknown date, the patients were vaccinated with improperly stored ROTATEQ orally, lot # L033543, expiry date 30-MAY-2017. There was temperature excursion of 32.9F for 4 hours (supported). No adverse effects were reported. Additional information had been requested.
Pt adm 1st dose of Hep B vax (recomb) subsequently exp swelling in her hands which persisted for 10 days; No further details were provided;
Pt recvd 1st Engerix-B vax on 25JUL91 & later that evening became cold & clammy, exp weakness especially arms, sl nausea which passed & had a runny nose; no tx given for events; 26JUL91 pt is "now feeling normal again";
Symptoms of COVID began on 7/22, tested positive for COVID on 7/26, and was admitted to the hospital on 7/27/2021.
Recipient had difficulty breathing, swallowing and chill. Patient did not want to use epi pen . Diphenhydramine 25mg was taken. Patient felt better for about an hour and started having the same symptoms. Another diphenhydramine 25mg was given. Patient was observed by the nurse at the facility until after 5:30 pm and was able to drive home.
Pt. woke up from nap at 6 pm. Discovered a golf-ball sized nodule at inner aspect lower left axillary region. Soreness noted, no redness.  She went to facility, was seen by provider who thought Tdap was the etiology of the swollen lymph node.  She had no redness at site and her WBC count was not elevated.  The nodule is slowly reducing in size and becoming less tender.
people who are getting a 3rd Moderna shot who are not immunocompromised; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by a consumer and describes the occurrence of EXTRA DOSE ADMINISTERED (people who are getting a 3rd Moderna shot who are not immunocompromised) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced EXTRA DOSE ADMINISTERED (people who are getting a 3rd Moderna shot who are not immunocompromised). At the time of the report, EXTRA DOSE ADMINISTERED (people who are getting a 3rd Moderna shot who are not immunocompromised) had resolved.            No concomitant medications were not reported. No treatment medications were not provided.
moderna 1 5/4/2021  0.5/0.25ml     moderna 2   6/1/2021   0.5/0.25ml     moderna 3 0.5/0.25ml     moderna 3 booster sht should be 1/2 dose of 1 & 2   i waserror given full doze  hosp should NOT allow prefill syringe and give all pt same dose   I was overdose   in vovid19 vaccine.    RN who gave the shot at the hospital.   Hosp  manager supervisor is responsible for this lazy and improper care to pt.   exclude me unknown how many pt got full dose as booster instead of 1/2 dose.   I happen lucky to catch this serious error and wrong name spelling.
I got my first dose of the Modena vaccine on March 29th, only had local injection site pain for 3 days, then I did not have any other sides effects. Unfortunately 3 weeks later, my legs and back waist started growing rashes, total about 30 which were itchy, these rashes slowing faded in 3-4 days. Starting on the 19th, my waist and left hip are in pain and I can hardly move and can't bend. The pain changes place to place and from sometimes being very light and sometimes strong. It has been 6 days now, although pain is not getting worse. I am thinking that these symptoms are due to my body overacting in response to the vaccine, resulting in spine and hip joint inflammation inducing pain.
Got blood clots in legs and lungs. Died  feburary 14th 2022
Horrible itching clawing my face and body, trouble breathing, fever, headache, diarrhea, tongue felt swollen
Information has been received from a legal firm regarding a case in litigation concerning a 12 month old male who was vaccinated with MMR II. It has been alleged that as a result of the vaccination administered during the period from 3/30/94 throught 4/17/98, the pt was exposed to very high doses of mercury and other heavy metals contained in the highly toxic preservative thimerosal. It was further alleged that the use of the live MMR II injured the pt by causing mercury toxicity and associated neurological injuries with specific symptoms and sequelae. It was reported that at 12 months old, the pt began struggling with the developmental milestones. At approximately 4 years old, the pt was neurologically devasted by the accumulation of mercury in his body, having been exposed via multi source exposure including but not limited to power plant emissions, amalgams, and IM vaccinations, either alone or in conjunction with the MMR II. It was reported that the pt's mother, a dentist, had amalgams placed in her mouth and implanted amalgams into her pt's mouth while she was pregnant. As a result of the cumulative doses of mercury in the environment, the amalgam fillings and the thimerosal-containing products the pt received as an infant and while in a prenatal state through the umbilical cord from his mother, he now suffers severe and permanent injuries from the toxic neuroloigcal effects of mercury poisoning. Also, the pt had been diagnosed as being autistic which was later determined to be mercury induced encephalopathy with autistic features and/or viral induced encephalitis with autistic features, a condition whose symptoms are materially indistinguishable to those of mercury poisoning. Additionally, the pt suffered the measles virus within his spinal fluids as a result of vaccination with MMR II. Upon internal review, mercury poisoning, neurological injuries, mercury induced encephalopathy with autistic features, viral induced encephalitis with autistic features, and measles virus in the spinal fluids were considered other important medical events (OMIC). No further info is available.
Consistent swelling of the left clavicular lymph node, ongoing  for 10 weeks
Developed warmth, erythema, pain, and induration almost 48 hours after vaccine administration with one day of fever. Treated as cellulitis vs large local reaction to vaccine.
Patient initially had redness in right thigh. Was treated conservatively with warm compresses and over the counter pain relievers.  Redness progressed and cellulitis at injection site was diagnosised.  Injections given on 08/23/2007.  Patient treated with course of Keflex on 08/27/07
Sore arm; Little stiffness of the neck; Runny nose; This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN EXTREMITY (Sore arm), MUSCULOSKELETAL STIFFNESS (Little stiffness of the neck) and RHINORRHOEA (Runny nose) in a 75-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced PAIN IN EXTREMITY (Sore arm), MUSCULOSKELETAL STIFFNESS (Little stiffness of the neck) and RHINORRHOEA (Runny nose). At the time of the report, PAIN IN EXTREMITY (Sore arm), MUSCULOSKELETAL STIFFNESS (Little stiffness of the neck) and RHINORRHOEA (Runny nose) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No relevant concomitant medications were reported.   No treatment information was provided.
awakened 1AUG95 w/"real bad migraine on leg & side of head", says lt side of body numb, arm, hand numb to fingers, drags foot, limps & c/o muscle spasms;denies hx hi BP; inj site red, swollen (size of quarter) urged see MD immed
Information has been received from a registered nurse and a physician via a company representative concerning an 18 year old female who on 27-DEC-2006 was vaccinated intramuscularly with one dose of GARDASIL (lot 653978/0955F). On 27-DEC-2006 the patient passed out after getting GARDASIL. The patient sought unspecified medical attention. It was not reported if the patient recovered. Additional information has been requested. This is in follow-up to report (s) previously submitted on 2/14/2007. Initial and follow-up information has been received from a registered nurse via a company representative concerning an 18 year old female student with no reported allergies who on 27-DEC-2006, at 9:30AM. was vaccinated intramuscularly into the left deltoid with a first dose of GARDASIL vaccine (Lot# 653978/0955F). There was no illness at the time of vaccination. Initial information indicated that on 27-DEC-2006 the patient passed out after getting GARDASIL vaccine. Follow-up information from the nurse clarified that the "patient felt faint after the injection but did not faint". The patient told the nurse that she had not eaten so they gave her some "coke" and after she sat for 15 minutes she felt better. The patient was reported as recovered on 27-DEC-2006. Additional information is not expected.
Got very sick after my second vaccine shot; This spontaneous case was reported by an other health care professional and describes the occurrence of ILLNESS (Got very sick after my second vaccine shot) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Concurrent medical conditions included Cancer.    On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced ILLNESS (Got very sick after my second vaccine shot). At the time of the report, ILLNESS (Got very sick after my second vaccine shot) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Antibody test: got no antibodies Got no antibodies.     For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant drug details were reported. No treatment details were reported.  Patient reported that, the patient got very sick after second vaccine shot and got no antibodies.
This spontaneous report as received from a medical assistant refers to an unspecified number of patients of unknown age and gender. No concurrent conditions, medical history and drug allergies were reported. On 18-JUN-2015, the patients were vaccinated with improperly stored doses of (Merck) PROQUAD (lot number L005295 and expiry date 17-AUG-2016) (dosing, regimen, route were unknown). No concomitant medications were reported. No adverse effects were reported. There was no product quality issue reported. Follow up information was received on 10-JUL-2015. It was reported that lot number L005295 with an expiry date of 17-AUG-2016 is a valid lot number for (Merck) PROQUAD. On 03-AUG-2015, a phone call was made to the certified medical assistant. The phone call went directly to voice mail. A voice mail message was left requesting that the certified medical assistant return the phone call. Additionally, a request was made for patient identifiers, lot number, expiration date and date of vaccination. All telephone attempts to obtain follow up information have been unsuccessful. Follow up information has been received from the reporting Certified Medical Assistant (C.M.A.) during a phone call on 05-AUG-2015. The C.M.A. reported that she would have to research the request made for patient identifiers, lot number and expiration date and dates of vaccination. Follow-up information has been received from the medical assistant's clinic on 22-OCT-2015, regarding a 4-year-old patient of unknown gender. On 14-JUL-2015, the patient was vaccinated with a dose of improperly stored (Merck) PROQUAD (albumin status HSA), lot # was confirmed to be L005295. This is one of several reports received from the same source. Additional information has been requested. Patient's details, event, product information and narrative were updated.
Lightheadedness, fever, chest pain, tingling hands, leg pain, weakness, inflammation in muscles all over body. Started immediately after the shot
24 hours after vaccine, redness, swelling, warm to touch, local reaction at injection site.
she could "barely walk after the 2nd dose/had to help her walk around for a couple days; This is a spontaneous report from a contactable consumer. This consumer reported for a female patient (reporter's wife) that:  A female patient of unspecified age received second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE; Solution for injection; Lot number: unknown) via an unspecified route of administration on an unspecified date as single dose for COVID-19 immunization. Medical history and concomitant medications were not reported. Patient previously received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE; Solution for injection; Lot number: unknown) via an unspecified route of administration on an unspecified date as single dose for COVID-19 immunization and was fine after first dose. On an unspecified date after receiving second dose of vaccination, patient could barely walk. Patient couldn't walk, her husband (reporter) had to help her walk around for a couple days. Reported also mentioned that patient had loss of both his mother and grandmother, although they did not pass due to COVID related illnesses. When probing for information regarding the caller's wife he reports she was ok now, he was concerned for her when it happened.  The lot number for the vaccine, [BNT162B2], was not provided and will be requested during follow up.
sore arm; pain in thigh; body pains; extreme fatigue; vomiting; fever; This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN EXTREMITY (sore arm), PAIN IN EXTREMITY (pain in thigh), PAIN (body pains), FATIGUE (extreme fatigue) and VOMITING (vomiting) in a 73-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     The patient's past medical history included COVID-19 in April 2020. Concomitant products included AMOXYCILLIN [AMOXICILLIN] for an unknown indication.   On 22-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 23-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 23-Mar-2021, the patient experienced PAIN IN EXTREMITY (sore arm), PAIN IN EXTREMITY (pain in thigh), PAIN (body pains), FATIGUE (extreme fatigue), VOMITING (vomiting) and PYREXIA (fever). The patient was treated with PARACETAMOL (TYLENOL) at a dose of UNK dosage form. At the time of the report, PAIN IN EXTREMITY (sore arm), PAIN (body pains), FATIGUE (extreme fatigue), VOMITING (vomiting) and PYREXIA (fever) had resolved and PAIN IN EXTREMITY (pain in thigh) had not resolved. Not Provided    DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): In April 2020, SARS-CoV-2 antibody test: positive (Positive) Positive.         Concomitant medications taken by the patient also included an inhaler.     This case was linked to US-MODERNATX, INC.-MOD-2021-060747 (E2B Linked Report). This case was linked to MOD-2021-060747 (Patient Link).   Most recent FOLLOW-UP information incorporated above includes: On 19-Jul-2021: Followup received on 19-JUL-2021 contains no significant information.; Sender's Comments:  US-MODERNATX, INC.-MOD-2021-060747:Case for first dose
Took the shot but did not protect me/ Suspected vaccination failure; Shingles; This serious case was reported by a consumer via interactive digital media and described the occurrence of vaccination failure in a patient who received Herpes zoster (Shingles vaccine) for prophylaxis.   On an unknown date, the patient received Shingles vaccine. On an unknown date, an unknown time after receiving Shingles vaccine, the patient experienced vaccination failure (Verbatim: Took the shot but did not protect me/ Suspected vaccination failure) (serious criteria GSK medically significant) and shingles (Verbatim: Shingles). The patient was treated with intravenous fluid (nos) (Infusion). The outcome of the vaccination failure was unknown and the outcome of the shingles was not reported.   It was unknown if the reporter considered the vaccination failure and shingles to be related to Shingles vaccine.     It was unknown if the company considered the vaccination failure and shingles to be related to Shingles vaccine.   Additional Information: GSK Receipt Date: 10-JUN-2023 This case was reported by a patient via interactive digital media. The patient reported that he or she received Shingles vaccine but the vaccine did not protect him or her. The patient stated that he or she have shingles for six months. The patient took infusion to improve his or her immune system. This case was considered as suspected vaccination failure as details regarding completion of primary schedule, time to onset for shingles and laboratory confirmation regarding shingles were unknown at the time of reporting. Follow-up would not possible as no contact details were available.
Headache and nausea: 04/07/2021 at approx 9pm until bed (10pm). Woke up at 3:30am for work. Headache not very bad. Nausea much worse. Fatigue. Called out sick from work.   Very bad nausea from 04/07/21 at 9pm until 04/09/21 at 11:30pm (bedtime). Vomited twice and felt fatigued during that period of time. Woke up on 04/10/21 at 8:30am feeling much better.
Patient received second COVID-19 at Pharmacy. There was pain after the administration and the pain worsened as time went by. Pain has gotten to a point where patient had to go see a doctor in March 2022. Patient plans to attend physical therapy due to the pain.